Compound heterozygous SLC19A3 mutations further refine the critical promoter region for biotin-thiamine-responsive basal ganglia disease

Mutations in the gene SLC19A3 result in thiamine metabolism dysfunction syndrome 2, also known as biotin-thiamine-responsive basal ganglia disease (BTBGD). This neurometabolic disease typically presents in early childhood with progressive neurodegeneration, including confusion, seizures, and dysphagia, advancing to coma and death. Treatment is possible via supplement of biotin and/or thiamine, with early treatment resulting in significant lifelong improvements. Here we report two siblings who received a refined diagnosis of BTBGD following whole-genome sequencing. Both children inherited compound heterozygous mutations from unaffected parents; a missense single-nucleotide variant (p.G23V) in the first transmembrane domain of the protein, and a 4808-bp deletion in exon 1 encompassing the 5′ UTR and minimal promoter region. This deletion is the smallest promoter deletion reported to date, further defining the minimal promoter region of SLC19A3. Unfortunately, one of the siblings died prior to diagnosis, but the other is showing significant improvement after commencement of therapy. This case demonstrates the power of whole-genome sequencing for the identification of structural variants and subsequent diagnosis of rare neurodevelopmental disorders.

[1]  Toshihiro Tanaka The International HapMap Project , 2003, Nature.

[2]  A. Hazell,et al.  Modeling neurodegenerative disease pathophysiology in thiamine deficiency: Consequences of impaired oxidative metabolism , 2011, Neurochemistry International.

[3]  S. Khan,et al.  Biotin-responsive basal ganglia disease revisited , 2013, Neurology.

[4]  N. Vaziri,et al.  Thiamin uptake by the human-derived renal epithelial (HEK-293) cells: cellular and molecular mechanisms. , 2006, American journal of physiology. Renal physiology.

[5]  G. Gascon,et al.  Biotin-responsive basal ganglia disease: a novel entity. , 1998, Brain : a journal of neurology.

[6]  Da-Neng Wang,et al.  Structure and Mechanism of the Glycerol-3-Phosphate Transporter from Escherichia coli , 2003, Science.

[7]  M. Alfadhel,et al.  Treatment of biotin-responsive basal ganglia disease: Open comparative study between the combination of biotin plus thiamine versus thiamine alone. , 2015, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[8]  J. Zempleni,et al.  The nuclear abundance of transcription factors Sp1 and Sp3 depends on biotin in Jurkat cells. , 2003, The Journal of nutrition.

[9]  David J. States,et al.  Identification of protein coding regions by database similarity search , 1993, Nature Genetics.

[10]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[11]  A. Yamaguchi,et al.  Complete Cysteine-scanning Mutagenesis and Site-directed Chemical Modification of the Tn10-encoded Metal-Tetracycline/H+ Antiporter* , 2001, The Journal of Biological Chemistry.

[12]  Hitoshi Suzuki,et al.  Mutations in a thiamine-transporter gene and Wernicke's-like encephalopathy. , 2009, The New England journal of medicine.

[13]  H. Smeets,et al.  Reply: Infantile Leigh-like syndrome caused by SLC19A3 mutations is a treatable disease. , 2014, Brain : a journal of neurology.

[14]  T. I. Vlasova,et al.  Biotin deficiency reduces expression of SLC19A3, a potential biotin transporter, in leukocytes from human blood. , 2005, The Journal of nutrition.

[15]  M. Gerstein,et al.  CNVnator: an approach to discover, genotype, and characterize typical and atypical CNVs from family and population genome sequencing. , 2011, Genome research.

[16]  S. Rahman,et al.  Treatable Leigh-like encephalopathy presenting in adolescence , 2013, BMJ Case Reports.

[17]  J. Marchant,et al.  Biotin-responsive basal ganglia disease-linked mutations inhibit thiamine transport via hTHTR2: biotin is not a substrate for hTHTR2. , 2006, American journal of physiology. Cell physiology.

[18]  Ellen T. Gelfand,et al.  The Genotype-Tissue Expression (GTEx) project , 2013, Nature Genetics.

[19]  S. Iwata,et al.  Structure and Mechanism of the Lactose Permease of Escherichia coli , 2003, Science.

[20]  Fanfan Zhou,et al.  The role of glycine residues in the function of human organic anion transporter 4. , 2004, Molecular pharmacology.

[21]  I. Jonassen,et al.  Novel SLC19A3 Promoter Deletion and Allelic Silencing in Biotin-Thiamine-Responsive Basal Ganglia Encephalopathy , 2016, PloS one.

[22]  J. Abdenur,et al.  Whole exome sequencing reveals compound heterozygous mutations in SLC19A3 causing biotin-thiamine responsive basal ganglia disease , 2014, Molecular genetics and metabolism reports.

[23]  T. Gillis,et al.  Biotin-responsive basal ganglia disease maps to 2q36.3 and is due to mutations in SLC19A3. , 2005, American journal of human genetics.

[24]  M. Alfadhel,et al.  Biotin-responsive basal ganglia disease should be renamed biotin-thiamine-responsive basal ganglia disease: a retrospective review of the clinical, radiological and molecular findings of 18 new cases , 2013, Orphanet Journal of Rare Diseases.

[25]  Andrew J. Hill,et al.  Analysis of protein-coding genetic variation in 60,706 humans , 2015, bioRxiv.

[26]  H. Said,et al.  In vitro and in vivo characterization of the minimal promoter region of the human thiamin transporter SLC19A2. , 2003, American journal of physiology. Cell physiology.

[27]  B. Wlodarczyk,et al.  Identification and characterization of the human and mouse SLC19A3 gene: a novel member of the reduced folate family of micronutrient transporter genes. , 2000, Molecular genetics and metabolism.

[28]  Q. Waisfisz,et al.  Exome sequencing reveals mutated SLC19A3 in patients withan early-infantile, lethal, encephalopathy , 2013, Brain : a journal of neurology.

[29]  T. Acker,et al.  Stress‐Induced Upregulation of SLC19A3 is Impaired in Biotin‐Thiamine‐Responsive Basal Ganglia Disease , 2014, Brain pathology.

[30]  C. Richelme,et al.  The severity of phenotype linked to SUCLG1 mutations could be correlated with residual amount of SUCLG1 protein , 2010, Journal of Medical Genetics.

[31]  R. Artuch,et al.  Reversible Lactic Acidosis in a Newborn With Thiamine Transporter-2 Deficiency , 2013, Pediatrics.

[32]  H. Said,et al.  Adaptive regulation of human intestinal thiamine uptake by extracellular substrate level: a role for THTR-2 transcriptional regulation. , 2013, American journal of physiology. Gastrointestinal and liver physiology.

[33]  H. Said,et al.  Characterization of the 5'-regulatory region of the human thiamin transporter SLC19A3: in vitro and in vivo studies. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[34]  K. Amunts,et al.  Biotin-responsive Basal Ganglia disease: a treatable differential diagnosis of leigh syndrome. , 2013, JIMD reports.

[35]  C. Ferreira,et al.  Biotin‐thiamine responsive basal ganglia disease: Identification of a pyruvate peak on brain spectroscopy, novel mutation in SLC19A3, and calculation of prevalence based on allele frequencies from aggregated next‐generation sequencing data , 2017, American journal of medical genetics. Part A.

[36]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[37]  Nan Li,et al.  Identification of Amino Acids Essential for Estrone-3-Sulfate Transport within Transmembrane Domain 2 of Organic Anion Transporting Polypeptide 1B1 , 2012, PloS one.

[38]  N. Longo,et al.  Glutaric acidemia type 1 , 2006, American journal of medical genetics. Part C, Seminars in medical genetics.

[39]  Sriram Subramaniam,et al.  Three-dimensional structure of a bacterial oxalate transporter , 2002, Nature Structural Biology.

[40]  James Y. Zou Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.

[41]  T. Meitinger,et al.  Infantile Leigh-like syndrome caused by SLC19A3 mutations is a treatable disease. , 2014, Brain : a journal of neurology.

[42]  R. Artuch,et al.  Thiamine transporter-2 deficiency: outcome and treatment monitoring , 2014, Orphanet Journal of Rare Diseases.

[43]  R. Płoski,et al.  New perspective in diagnostics of mitochondrial disorders: two years’ experience with whole-exome sequencing at a national paediatric centre , 2016, Journal of Translational Medicine.

[44]  P. Dudeja,et al.  Expression and promoter analysis of SLC19A2 in the human intestine. , 2002, Biochimica et biophysica acta.

[45]  A. Ribes,et al.  Free-thiamine is a potential biomarker of thiamine transporter-2 deficiency: a treatable cause of Leigh syndrome. , 2016, Brain : a journal of neurology.

[46]  J. Marchant,et al.  Targeting and Trafficking of the Human Thiamine Transporter-2 in Epithelial Cells* , 2006, Journal of Biological Chemistry.

[47]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[48]  R. Wibom,et al.  Biotin and Thiamine Responsive Basal Ganglia Disease--A vital differential diagnosis in infants with severe encephalopathy. , 2016, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[49]  H. Glaeser,et al.  Relevance of conserved lysine and arginine residues in transmembrane helices for the transport activity of organic anion transporting polypeptide 1B3 , 2010, British journal of pharmacology.

[50]  R. Wilson,et al.  BreakDancer: An algorithm for high resolution mapping of genomic structural variation , 2009, Nature Methods.

[51]  Christian H. Ahrens,et al.  Protter: interactive protein feature visualization and integration with experimental proteomic data , 2014, Bioinform..

[52]  N. Matsumoto,et al.  Biotin-responsive basal ganglia disease: a case diagnosed by whole exome sequencing , 2015, Journal of Human Genetics.

[53]  Gabor T. Marth,et al.  A global reference for human genetic variation , 2015, Nature.

[54]  Xiaolin Zhu,et al.  An Evaluation of Copy Number Variation Detection Tools from Whole‐Exome Sequencing Data , 2014, Human mutation.

[55]  J. Obeso,et al.  Reversible generalized dystonia and encephalopathy from thiamine transporter 2 deficiency , 2012, Movement disorders : official journal of the Movement Disorder Society.

[56]  Shane S. Sturrock,et al.  Geneious Basic: An integrated and extendable desktop software platform for the organization and analysis of sequence data , 2012, Bioinform..

[57]  H. Smeets,et al.  Exome sequencing reveals a novel Moroccan founder mutation in SLC19A3 as a new cause of early-childhood fatal Leigh syndrome. , 2013, Brain : a journal of neurology.

[58]  S. O. Smith,et al.  Helix packing in polytopic membrane proteins: role of glycine in transmembrane helix association. , 1999, Biophysical journal.

[59]  Helga Thorvaldsdóttir,et al.  Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration , 2012, Briefings Bioinform..

[60]  D. Galanaud,et al.  Biotin-responsive basal ganglia disease in ethnic Europeans with novel SLC19A3 mutations. , 2010, Archives of neurology.

[61]  H. Algahtani,et al.  Biotin–thiamine–responsive basal ganglia disease: catastrophic consequences of delay in diagnosis and treatment , 2017, Neurological research.

[62]  J. Marchant,et al.  Expression and functional contribution of hTHTR-2 in thiamin absorption in human intestine. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[63]  S. Tsuji,et al.  A wide spectrum of clinical and brain MRI findings in patients with SLC19A3 mutations , 2010, BMC Medical Genetics.